Current trends in the allocation of National Institute of Health funding of brain tumor research.

Background: The National Institute of Health (NIH) provides a sizable annual budget toward brain tumor research. However, funding allocation for specific pathologies remains poorly described. We aimed to characterize the current landscape of NIH funding toward brain tumors as a function of pathology.

Methods: NIHRePORTER was queried to identify studies focused on glioblastoma, pediatric glioma, oligodendroglioma, brain metastasis, meningioma, pituitary adenoma, and vestibular schwannoma, from 2000 to 2023. Studies with R, U, and P funding mechanisms were included. Data were compiled and assessed according to pathology.

Results: Across these 7 tumors, 3320 unique studies with R, U, or P funding mechanisms were identified from 2000 to 2023. These were conducted across 480 unique institutions. The sum of funds allocated to all studies was $1 607 662 631. Glioblastoma commanded the largest portion of funds, representing 54% of R mechanisms, 55% of R01-funded studies, 48% of U mechanisms, and 49% of P mechanisms, and accounted for 51% ($813 556 423) of total funding. Brain metastasis was the second most-funded tumor, representing 31% of all R mechanisms, 31% of all R01-funded studies, 26% of all U mechanisms, and 28% of all P mechanisms, and accounted for 29% ($472 715 745) of funding. The remaining 14% of R mechanisms, 26% of U mechanisms, and 23% of P mechanisms focused on the remaining pathologies, and accounted for 20% ($321 390 463) of funding.

Conclusions: The current landscape of NIH funding for brain tumor research indicates that awarded mechanisms prioritize malignant intra-axial malignancies. Despite their prevalence, skull base neoplasia is far less represented in NIH-funded studies.